Thiacetazone

Thioacetazone

Clinical data
Trade names	Conteben
Synonyms	Thiacetazone; Thiocetazone; Thioparamizone; Benzothiozane; 4-Acetylaminobenzaldehyde thiosemicarbazone; N-[4-[(Carbamothioylhydrazinylidene) methyl]phenyl]acetamide
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	J04AM04 (WHO)
Identifiers
IUPAC name N-{4-[(Ethanethioamidoimino)methyl]phenyl}acetamide
CAS Number	104-06-3
PubChem CID	9568512
ChemSpider	7843221 Y
UNII	MMG78X7SSR
KEGG	D08584 Y
ChEMBL	CHEMBL375492 Y
ECHA InfoCard	100.002.882
Chemical and physical data
Formula	C10H12N4OS
Molar mass	236.29 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(Nc1ccc(cc1)\C=N\NC(=S)N)C
InChI InChI=1S/C10H12N4OS/c1-7(15)13-9-4-2-8(3-5-9)6-12-14-10(11)16/h2-6H,1H3,(H,13,15)(H3,11,14,16)/b12-6+ Y Key:SRVJKTDHMYAMHA-WUXMJOGZSA-N Y
Y (what is this?)

Thioacetazone (INN, BAN), also known as amithiozone (USAN), is an oral antibiotic which is used in the treatment of tuberculosis. It has fallen into almost complete disuse due to toxicity and the introduction of improved anti-tuberculosis drugs like isoniazid. The drug has only weak activity against Mycobacterium tuberculosis and is only useful in preventing resistance to more powerful drugs such as isoniazid and rifampicin. It is never used on its own to treat tuberculosis; it is used in a similar way to ethambutol.

There is no advantage to using thioacetazone if the regimen used already contains ethambutol, but many countries in sub-Saharan Africa still use thioacetazone because it is extremely cheap. Use of thioacetazone is declining because it can cause severe (sometimes fatal) skin reactions in HIV positive patients.

The biological target of thioacetazone has proven elusive and its mechanism of action remains unknown, although it is thought to interfere with mycolic acid synthesis.

One of the documented adverse effects of thioacetazone is the excessive accumalation of serum (or blood plasma) in the brain. Another is weakening of the thyroid glands. These were found in a treatment combining conteben with PAS acid p-amino-salicylic acid.